Affinity Asset Advisors LLC Invests $8.02 Million in Enliven Therapeutics, Inc. $ELVN

Affinity Asset Advisors LLC acquired a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 400,000 shares of the company’s stock, valued at approximately $8,024,000. Enliven Therapeutics comprises about 1.1% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 27th largest holding.

Several other hedge funds have also recently added to or reduced their stakes in ELVN. Candriam S.C.A. acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at approximately $8,358,000. Franklin Resources Inc. boosted its position in shares of Enliven Therapeutics by 2,029.3% in the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after acquiring an additional 410,034 shares during the period. Marshall Wace LLP grew its stake in shares of Enliven Therapeutics by 2,886.9% in the second quarter. Marshall Wace LLP now owns 333,333 shares of the company’s stock worth $6,687,000 after acquiring an additional 322,173 shares during the last quarter. Russell Investments Group Ltd. increased its position in Enliven Therapeutics by 148,550.7% during the first quarter. Russell Investments Group Ltd. now owns 105,542 shares of the company’s stock worth $2,077,000 after acquiring an additional 105,471 shares during the period. Finally, Nuveen LLC bought a new position in Enliven Therapeutics during the first quarter worth $2,049,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $21.81 on Friday. The firm has a market cap of $1.29 billion, a P/E ratio of -11.85 and a beta of 0.35. The firm’s 50-day simple moving average is $20.87 and its 200-day simple moving average is $20.34. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $25.96.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. On average, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $21.33, for a total value of $266,625.00. Following the sale, the chief executive officer directly owned 902,892 shares in the company, valued at $19,258,686.36. This represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Joseph P. Lyssikatos sold 12,500 shares of Enliven Therapeutics stock in a transaction on Monday, October 20th. The shares were sold at an average price of $22.08, for a total value of $276,000.00. Following the transaction, the insider directly owned 915,188 shares of the company’s stock, valued at approximately $20,207,351.04. The trade was a 1.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 98,251 shares of company stock valued at $2,038,534. Corporate insiders own 25.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.